Impact of XPD Lys751Gln Genetic Polymorphism on Oxaliplatin-Based Regimen Induced Toxicities in Iraqi Colorectal Cancer Patients
DOI:
https://doi.org/10.31351/vol34iss1pp26-34Keywords:
Adverse events; ERCC2; NER pathway; platinum chemotherapy; polymorphismAbstract
The XPD Lys751Gln polymorphism may affect individual differences in DNA repair ability, which could increase a person's risk of developing toxicity when receiving oxaliplatin containing regimen in colorectal cancer patients. Therefore, assessment of XPD Lys751Gln polymorphism may generate crucial data for identifying individuals at high risk for serious adverse effects and thus choosing the best treatment option. Hence the aim of current research is to find out the association between XPD Lys751Gln polymorphism and oxaliplatin based regimen toxicities among sample of Iraqi population. 72 CRC who are on oxaliplatin based regimen were enrolled in the study and were followed for 4 cycles. Polymerase chain reaction (PCR) was used for genotyping, followed by sequencing. Toxicities were recorded before the start of each of the four cycles then the relationship between genetic polymorphism and observed toxicities were examined. There was no significant association between Lysn751 Gln genotypes and studied hematological and non-hematological toxicities. Taken together, The XPD Lys751Gln polymorphism cannot be considered a potential biomarker for platinum induced toxicity.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Cancer IAFRo. Colorectal Cancer Awareness Month 2022 2022 [Available from: https: // www .iarc.who.int/featured-news/ colorectal - cancer- awareness-month-2022/.
Al Alwan NA. Cancer control and oncology care in Iraq. In: Al-Shamsi HO A-GI, Iqbal F, Al-Awadhi A, editor. Cancer in the Arab World. 8. J Contemp Med Sci: Springer; 2022. p. 82-5.
Hanon BM, Al-Mohaimen Mohammad NA, Mahmood AS. CpG Island Methylator Phenotype (CIMP) Correlation with Clinical and Morphological Feature of Colorectal Cancer in Iraq patients. PAJO. 2015;8(2).
Mahood WS, Nadir MI, Tobal K, Asker BA. Methylation Status of p16 gene in Iraqi Colorectal Cancer Patients. Iraqi journal of biotechnology. 2014;13(2):237-47.
Akimoto N, Ugai T, Zhong R, Hamada T, Fujiyoshi K, Giannakis M, Wu K, Cao Y, Ng K, Ogino S. Rising incidence of early-onset colorectal cancer—A call to action. Nat. Rev. Clin. Oncol. 2021 Apr;18(4):230-43.
Aljarshawi M, Albadree H, Bahar H, Al-Imam A. Misleading Presentation of Colorectal Cancer in an Otherwise Healthy Patient. JFacMedBagdad. 2020;62(4):132-8.
Mahmood AH, Zeiny SM, Mahmood AS. Serological markers “CEA test & sAPRIL test” in Iraqi patients with colon cancer. JFacMedBagdad. 2017;59(4):317-20.
National Comprehensive Cancer Network NCCN. Colorectal Cancer 2021 [Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428.
Buyana B, Naki T, Alven S, Aderibigbe BA. Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy. Int J Mol Sci. 2022;23(19).
Wu C. Systemic Therapy for Colon Cancer. Surg Oncol Clin N Am. 2018;27(2):235-42.
Akdeniz N, Kaplan MA, Uncu D, İnanç M, Kaya S, Dane F, Küçüköner M, Demirci A, Bilici M, Durnalı AG, Koral L. The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study. Int. J. Colorectal Dis. 2021 Jun;36:1311-9.
Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007;25(1):102-9.
Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ. Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit. Rev. Oncol. Hematol. 2011;79(3):224-50.
Afifah NN, Diantini A, Intania R, Abdulah R, Barliana MI. Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy. Pharmgenomics Pers Med. 2020 Oct 8:427-44.
Kap EJ, Popanda O, Chang-Claude J. Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients. Pharmacogenomics J. 2016;17(7):755-94.
Sameer AS, Nissar S. XPD-The Lynchpin of NER: Molecule, Gene, Polymorphisms, and Role in Colorectal Carcinogenesis. Front Mol Biosci. 2018;5:23.
Lu X, Xiao S, Jin C, van der Straaten T, Li X. ERCC1 and XPD/ERCC2 Polymorphisms’ Predictive Value of Oxaliplatin‐Based Chemotherapies in Advanced Colorectal Cancer has an Ethnic Discrepancy: A Meta‐analysis. J. Clin. Lab. Anal. 2012;26(1):10-5.
Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem. Pharmacol. 2003;66(2):225-37.
Gul S, Khan A, Raza A, Khan I, Ehtisham S. Association of XPD Lys751Gln gene polymorphism with susceptibility and clinical outcome of colorectal cancer in Pakistani population: a case–control pharmacogenetic study. Genes & Genomics. 2020;42:1389-98.
Ruzzo A, Graziano F, Galli F, Giacomini E, Floriani I, Galli F, et al. Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. Sci. Rep. 2014;4(1):6828.
Kjersem J, Thomsen M, Guren T, Hamfjord J, Carlsson G, Gustavsson B, et al. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin. Pharmacogenomics J. 2016;16(3):272-9.
Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. The oncologist. 2004;9(1):8-12.
Lauschke VM, Ingelman-Sundberg M. Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation. NPJ Genom Med. 2020;5:9.
Goodyear MD, Krleza-Jeric K, Lemmens T. The Declaration of Helsinki. Bmj. 2007;335(7621):624-5.
Alrubaie A, Alkhalidi N, Abd-Alhusain S. A clinical study of newly-diagnosed colorectal cancer over 2 years in a gastroenterology center in Iraq. J. Coloproctology. 2019;39:217-22.
AJCC AJCoC. Colon and Rectum. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.
NCI. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [updated 19 April 2021. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J. 2013;13(5):403-9.
Katara P. Single nucleotide polymorphism and its dynamics for pharmacogenomics. Interdiscip Sci. 2014;6(2):85-92.
Mohammed SI, Zalzala MH, Gorial FI. The effect of TNF-alpha gene polymorphisms at-376 G/A,-806 C/T, and-1031 T/C on the likelihood of becoming a non-responder to etanercept in a sample of Iraqi rheumatoid arthritis patients. Iraqi J. Pharm. Sci. 2022 Dec 24;31(2):113-28.
Khudhur SS, Saleh ES, Alosami MH. The impact of rs767455 and rs1061622 polymorphisms on treatment outcomes in Iraqi ankylosing spondylitis patients taking etanercept. Egypt. J. Hosp. Med. 2023;90(2):3488-94.
Kathem SH. The prevalence of UGT1A1* 93 and ABCC5 polymorphisms in cancer patients receiving irinotecan-based chemotherapy at Al-Najaf Al-Ashraf. Iraqi J. Pharm. Sci. 2019;28(2):24-9.
Mohammed NS, Rasheed MK, Ghali HH, Ahmed SJ. Detection of Thiopurine S-Methyltransferase (TPMT) Polymorphisms TPMT* 3A, TPMT* 3B and TPMT* 3C in Children with Acute Lymphoblastic Leukemia. JFacMedBagdad. 2018;60(3):166-71.
Alridha AM, Kadhim DJ, Alkhazrajy AH. Association of the rs1128503 and rs1045642 polymor-phisms in the MDR-1 gene with steroid responsiveness in Iraqi children with idiopathic nephrotic syndrome. Pharm. Sci. Asia. 2023 Jul 1;50(3).
Ahmed FT, Ali SH, Al Gawwam GA. Integrin alpha-4 gene polymorphism in relation to natalizumab response in multiple sclerosis patients. Neurol. Asia. 2023 Jun 1;28(2).
Cortejoso L, García MI, García-Alfonso P, González-Haba E, Escolar F, Sanjurjo M, et al. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol. 2013;71(6):1463-72.
Duldulao MP, Lee W, Nelson RA, Ho J, Le M, Chen Z, et al. Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer. Cancer J. 2013;119(5):1106-12.
Boige V, Mollevi C, Gourgou S, Azria D, Seitz JF, Vincent M, et al. Impact of single‐nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD‐12/PRODIGE‐2 phase III trial. Int. J. Cancer. 2019;145(11):3163-72.
Lamas MJ, Duran G, Balboa E, Bernardez B, Touris M, Vidal Y, et al. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil–oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics J. 2011;12(3):433-42.
Salimzadeh H, Lindskog EB, Gustavsson B, Wettergren Y, Ljungman D. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival. BMC Cancer. 2020;20(1):409.
Boige V, Mendiboure J, Pignon J-P, Loriot M-A, Castaing M, Barrois M, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J. Clin. Oncol. 2010;28(15):2556-64.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
